AptaTargets is a biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. AptaTargets drug candidates start at preclinical stages and aims to reach phase 2 of clinical trials. Our candidates come from R&D activities developed at parent company Aptus Biotech in collaboration with research centers of reference.
AptaTargets starts its activity with a set of candidates for Acute Stroke treatment. These aptamers have been identified in vitro and their efficacy has been validated through in vitro and in vivo studies with outstanding results.